The agreement marks a major industrial shift for the Franklin Lakes-based company, which currently serves as the nation’s largest manufacturer of medical consumables. Over the next several years, BD plans to invest $19 billion into its domestic operations. Of this total, $3 billion is earmarked specifically for expanding production capacity across strategic sites in states including Nebraska, Utah, Texas, and South Carolina.

This expansion is projected to increase domestic output by 5 billion essential medical units annually, bringing BD’s share of U.S.-supplied consumables to approximately 80 percent. A central component of this initiative is the commitment to manufacture 100 percent of the company's needles in the U.S. using American-made steel. In exchange for these milestones, the government has provided relief from future Section 232 tariffs on covered products, granting the company greater long-term certainty for its capital planning. Tom Polen, chairman and CEO of BD, stated that the partnership aligns with a broader mandate to secure the national healthcare infrastructure against future disruptions.